CVS Joins Race to Sell Cheaper, 'Biosimilar' Drugs

CVS will begin selling cheaper biosimilar versions of prescription medications, starting with its own version of Humira, aiming to drive down the cost of biologic drugs and encourage investment in them.

cnet.com

Relevant topic timeline:

8/23/2023

CVS pushes into making cheaper versions of complex drugs with new discount Humira

CVS Health is partnering with Sandoz to produce a cheaper version of the arthritis drug Humira, as part of its venture into the biosimilars market.

8/23/2023

CVS Health Enters Biosimilars Market With New Subsidiary Cordavis

CVS Health has launched Cordavis, a subsidiary focused on bringing high-quality biosimilar products to the market to reduce drug costs and ensure access to affordable medications in the United States, with plans to develop a portfolio of biosimilar products and partner with Sandoz to commercialize lower-priced biosimilars.